Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€399.40

€399.40

2.780%
10.8
2.780%
€404.41
 
01.03.24 / Tradegate WKN: 882807 / Symbol: VRTX / Name: Vertex / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Vertex Pharmaceuticals Inc. Stock

Vertex Pharmaceuticals Inc. gained 2.780% today.
The stock is one of the favorites of our community with 35 Buy predictions and 2 Sell predictions.
With a target price of 404 € there is a slightly positive potential of 1.15% for Vertex Pharmaceuticals Inc. compared to the current price of 399.4 €.
Our community identified positive and negative aspects for Vertex Pharmaceuticals Inc. stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Vertex Pharmaceuticals Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.

Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years

Pros
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Vertex Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Vertex Pharmaceuticals Inc. 2.780% 0.491% 0.100% 46.220% 7.467% 128.725% 136.583%
Amgen Inc. 2.370% -3.216% -13.329% 16.866% -0.691% 37.222% 53.919%
Incyte Corp. 0.850% -2.644% 0.147% -25.322% -3.948% -17.587% -30.047%
Exact Sciences 2.160% 3.199% -6.751% -6.336% -19.977% -52.870% -32.967%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-29

Vertex Pharmaceuticals Inc (VRTX) has been growing consistently in the Biotechnology & Medical Research industry in recent years, as indicated by its financial statements. The company's financials, from its balance sheets to its income and cash flow statements, exhibit a strong growth in its assets, revenues, and profits.

Vertex has shown significant growth in total assets, as evidenced by a consistent increase from almost $11.75 billion in 2020 to over $18.15 billion in 2022. This growth highlights the company's strong financial position, enabling it to capitalize on investment opportunities and fuel further expansion.

The total revenue Vertex generated also increased from over $6.2 billion in 2020 to nearly $8.9 billion in 2022. The steady rise in sales is a positive sign for investors and points to the company's successful execution of its growth strategy.

Comments

Prediction Buy
Perf. (%) 3.15%
Target price 406.868
Change
Ends at 20.02.25

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $440.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 1.49%
Target price 478.126
Change
Ends at 15.02.25

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $515.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 3.42%
Target price 409.068
Change
Ends at 06.02.25

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $440.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Show more

News

CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst: https://g.foolcdn.com/editorial/images/766837/lab-research-scientists-women-in-stem.jpg
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst

Just one day after the ascendant biotech CRISPR Therapeutics (NASDAQ: CRSP) reported its fourth-quarter earnings on Feb. 21, Chardan Capital analyst Geulah Livshits raised her price target for the

bluebird bio: How to play LEAPS options for growth and income: https://www.marketbeat.com/logos/articles/med_20240226111048_option-blue-stock.jpg
bluebird bio: How to play LEAPS options for growth and income

Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT from CRISPR Therapeutics AG

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow: https://g.foolcdn.com/editorial/images/766684/gettyimages-1335027284.jpg
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

Vertex Pharmaceuticals (NASDAQ: VRTX) has built a cystic fibrosis (CF) treatment empire that brings in billions of dollars in earnings annually. And just recently, the company demonstrated it could